D. K. Armstrong - Concepedia

Author

D. K. Armstrong

Sidney Kimmel Cancer Center

Also Known As

D Armstrong, D. Armstrong, D. K. Armstrong, D.K. Armstrong, DK Armstrong

Publications

337

Citations

H-Index

Concepts

All Affiliations

Sidney Kimmel Cancer Center Johns Hopkins University National Cancer Institute

About

D. K. Armstrong is an author at Sidney Kimmel Cancer Center specializing in medicine, oncology, and cancer therapeutics.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	7	7	203
2	Obstetrics	5	5	128
3	Pathology	4	4	85
4	Health Sciences	1	1	64
5	Immunology	1	1	11

D. K. Armstrong

Publications

263

Citations

H-Index

Page 1

	Year	Citations
The role of nonrandomized trials in the evaluation of oncology drugs Richard Simon, GM Blumenthal, Rothenberg Ml, Clinical Pharmacology & Therapeutics Oncology DrugsCancer ManagementClinical EndpointPharmacotherapyMetronomic Chemotherapy	2015	64
Preliminary results of a phase II study: PD-1 blockade in mismatch repair–deficient, recurrent or persistent endometrial cancer A. Nickles Fader, Luis A. Díaz, D. K. Armstrong, Gynecologic Oncology Pd-1 BlockadeMedicineGynecologyPreliminary ResultsImmune Checkpoint Inhibitor	2016	44
Exploratory phase II efficacy study of MORAb-003, a monoclonal antibody against folate receptor alpha, in platinum-sensitive ovarian cancer in first relapse D. K. Armstrong, Annette Bicher, Robert L. Coleman, Journal of Clinical Oncology MedicineTumor GrowthFolate Receptor AlphaPharmacologyCancer Growth	2008	35
Efficacy and safety of topotecan in the treatment of advanced ovarian carcinoma. W ten Bokkel Huinink, J. Carmichael, D. K. Armstrong, PubMed	1997	30
BRCA1 expression in a large series of sporadic ovarian carcinomas: a Gynecologic Oncology Group study Melissa M. Thrall, Holly H. Gallion, Richard J. Kryscio, International Journal of Gynecological Cancer	2006	30
Efficacy and safety of farletuzumab, a humanized monoclonal antibody to folate receptor alpha, in platinum-sensitive relapsed ovarian cancer subjects: Final data from a multicenter phase II study. A. J. White, Robert L. Coleman, D. K. Armstrong, Journal of Clinical Oncology Cancer ManagementGynecologyPathologyFirst RelapseHumanized Monoclonal Antibody	2010	23
Taxol: A unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms McGuire Wp, EK Rowinsky, NB Rosenhein, International Journal of Gynecology & Obstetrics Significant ActivityMedicinePathologyGynecologyUnique Antineoplastic Agent	1990	16
A phase 1 study of MORAb-009, a monoclonal antibody against mesothelin in pancreatic cancer, mesothelioma and ovarian adenocarcinoma D. K. Armstrong, Daniel A. Laheru, W. W., Journal of Clinical Oncology ImmunologyPathologyImmunotherapeuticsCancer BiologyTumor Biology	2007	11
A multi-institutional double-blind phase II study evaluating response and surrogate biomarkers to carboplatin and nab-paclitaxel (CP) with or without vorinostat as preoperative systemic therapy (PST) in HER2-negative primary operable breast cancer (TBCRC008). R. M. Connolly, Stacie C. Jeter, Jane Zorzi, Journal of Clinical Oncology Surrogate BiomarkersSurgical OncologyOncologyBreast OncologyPharmacology	2010	10

Page 1